Main menu

R&D Platforms

R&D Platforms

Investing in Next Generation Approaches to Enable Tomorrow’s Innovative Therapies

Pfizer’s pipeline contains next generation therapies that include small-molecule therapies, large-molecule biologics, and vaccines. For each of these types of compounds, we use cutting-edge platforms to bring best-in-class therapies to patients.

Key R&D Platforms

  • Precision Medicine: Precision medicine entails using cutting-edge science, biology, and medical knowledge to select the right targets, develop the right therapy/combination therapy, and identify the patients who are more likely to respond to a specific therapy.

    Precision Medicine Image

     

  • Therapeutic Vaccines: Pfizer is expanding the application of vaccines to include therapeutic vaccines under investigation with the potential to target chronic conditions or treat diseases. We are exploring whether vaccines can do more than prevent disease. We believe vaccines may be able to treat disease by stimulating specific immune responses. Pfizer researching therapeutic vaccines for smoking cessation, allergic rhinitis/asthma and cancer.
     
  • Antibody Drug Conjugates (ADCs): ADCs are highly promising therapies that provide targeted delivery of an antibody with a small-molecule therapy to treat disease. While ADCs have the potential to treat a variety of diseases, our most advanced programs are in oncology -combining highly selective antibodies, which are large-molecular biologics that can find cancerous cells, with a small-molecule therapy designed to attack a tumor.

     

    Hear Bob Abraham discuss antibody drug conjugates, a key technology focus in the Oncology Research Unit.

  • Tissue-targeted New Chemical Entities (NCEs): Pfizer is applying next-generation technology to enhance selectivity of small molecules to target specific tissues and deliver therapy to localized areas.
     
  • Next-Generation Biologics: Pfizer is building on its expertise to design the next biologic therapies with the goal of delivering great potency and specificity. In some cases, this includes combining the activity of multiple anti-bodies that improve the treatments for cancer, rare diseases, autoimmune diseases and other conditions.
     

We believe innovation not only calls for the right type of technology to be matched to a specific medical need, but may also require new ways of combining technologies. This broad expertise – and a commitment to knowledge-sharing – is crucial in developing the therapies of tomorrow that will matter most for patients.